Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E, Prat A. Brasó-Maristany F, et al. Among authors: griguolo g. Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3. Nat Commun. 2020. PMID: 31959756 Free PMC article. Clinical Trial.
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Among authors: griguolo g. Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Breast Cancer Res Treat. 2017. PMID: 28289852
Olaparib for the treatment of breast cancer.
Griguolo G, Dieci MV, Guarneri V, Conte P. Griguolo G, et al. Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30. Expert Rev Anticancer Ther. 2018. PMID: 29582690 Review.
Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Dieci MV, et al. Among authors: griguolo g. Breast Cancer Res. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. Breast Cancer Res. 2018. PMID: 29929548 Free PMC article.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. Guarneri V, et al. Among authors: griguolo g. Ann Oncol. 2019 Jun 1;30(6):921-926. doi: 10.1093/annonc/mdz055. Ann Oncol. 2019. PMID: 30778520 Free PMC article. Clinical Trial.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. Prat A, et al. Among authors: griguolo g. J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042. J Natl Cancer Inst. 2020. PMID: 31037288 Free PMC article.
81 results